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Natural killer T (NKT) cells lie at the interface between
the innate and adaptive immune systems and are impor-
tant mediators of tumor immunosurveillance. This
CD1d-restricted lymphoid population recognizes lipid
antigen and can rapidly produce an array of cytokines
and chemokines to modulate the host immune response.
In tumor immunity, two NKT cell subsets (type I and
type II) have contrasting roles in which they not only
distinctly impact innate and adaptive immune cell popu-
lations, but also cross-regulate one another. Type I NKT
cells are usually associated with the promotion of tumor
immunity whereas type II NKT cells seem to suppress
it. Previous studies showed that type II NKT cells nega-
tively impact CD8+ T cells; however, little is known
about their effect on CD4+ T helper subsets. In this
study, we investigated how CD4+ T cell subsets are
affected by type II NKT cells activated with sulfatide, an
endogenous glycolipid antigen known to activate type II
NKT cells. Naïve ovalbumin (OVA) specific CD4+
T cells isolated from DO11.10 transgenic mice were
either tested ex vivo, or polarized in vitro into T helper
subsets (Th1, Th2 and Th17). CFSE dilution and ELISAs
were used to assess CD4+ T cell proliferative and cytokine
responses upon antigenic stimulation in the presence or
absence of sulfatide-activated type II NKT cells. We found
that activated type II NKT cells significantly inhibited
proliferation of naïve CD4+ T cells. The differentiated
activated/memory subsets appeared to be less susceptible
to such suppression. Ongoing elucidation of these inter-
actions and mechanisms may not only augment our und-
erstanding of CD4+ T cell regulation, but also improve
our capability to utilize type II NKT cells for clinical
applications.
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